Deltex Medical Regulatory News (DEMG)

4 Apr 2005 09:17

Deltex Medical Group PLC04 April 2005 Deltex Medical Group plc Independent Validation of UK Market Position 4 April 2005 - Deltex Medical Group plc ("Deltex Medical" or the "Company")today announces the results of an independent survey of cardiac outputmonitoring in England and Wales. Doctors from the Chelsea and Westminster and Royal Marsden Hospitals in Londonsurveyed two hundred and twenty-six adult intensive care units ("ICUs') inEngland and Wales and asked them how many types of cardiac output ('CO')monitoring were available at their unit and which of them was the mostpreferred. The survey, which was presented at the 25th International Symposium on IntensiveCare and Emergency Medicine in Brussels, found that: • "The majority of the ICUs in England and Wales have two or more CO monitoring techniques available. • "The most popular technique for CO monitoring in England and Wales is Oesophageal Doppler suggesting less invasive techniques are preferred." The survey found that 53% of ICUs in England and Wales had an oesophagealDoppler monitor device and that in 41% of ICUs it was the most popular (i.e.oesophageal Doppler monitoring is the preferred technique in nearly 80% of theunits where the technology is available). By contrast, the most common COmonitoring device remains the long established Pulmonary Artery Cathetertechnology which is available in 76% of ICUs, but is only the preferred devicein 20% of ICUs. The Company's market knowledge confirms that its CardioQTMmonitor is by far the most common Oesophageal Doppler device in the UK. Andy Hill, Deltex Medical's Chief Executive, said: "It is encouraging that therelative merits of the CardioQ are so firmly recognised in the UK intensive careenvironment. There is considerable scope for further growth in this part of ourtarget market as well as in the far larger operating theatre part of it where wehave the additional benefit of 'first-mover' advantage." For further information, please contact:- Deltex Medical Group plc 01243 774 837Nigel Keen, ChairmanAndy Hill, Chief ExecutiveEwan Phillips, Finance Director Financial DynamicsDavid Yates/Lucy Briggs 0207 831 3113 Notes for Editors The CardioQ incorporates the Company's proprietary software and a smalldiameter, easy-to-use, minimally invasive, disposable oesophageal probe that isused for transmitting and receiving an ultra-sound signal. By using thistechnology, the CardioQ provides clinicians with the ability to haemodynamicallyoptimise critically ill patients and those undergoing routine moderate to majorsurgery through the controlled administration of fluid and drugs. Haemodynamicoptimisation has been scientifically proven to improve the speed and quality ofpatient recovery and reduce hospital stay. There are already over 1,250 CardioQs currently in use in hospitals worldwideand distribution arrangements are in place in over 30 countries. In addition,there are currently more than 90 clinical publications on the use of the CardioQwhich have repeatedly:- • validated the results of the Monitor against known standards for measuring cardiac output, demonstrating that the technology works • proved that the CardioQ works in a wide range of surgical procedures • demonstrated that the Company's technology provides significant health and economic benefits by helping to reduce post-operative complications and length of hospital stays by an average of 30 to 40 per cent for a wide range of patients. This information is provided by RNS The company news service from the London Stock Exchange